Short answer
Penumbra Inc (PEN) filed its Q3 2017 10-Q quarterly report on Nov 7, 2017 for the quarter ended Sep 30, 2017.
Penumbra Inc Q3 2017 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $83.9M, up 24.9% YoY from $67.2M
- Peripheral Vascular fastest growth, $25.2M, up 28.4% YoY
- Gross margin 65.3% vs 63.8% YoY, operating margin 0.8% vs (2.0%)
- Cash $65.6M and marketable investments $153.2M at September 30, 2017
- Nine-month operating cash flow $13.6M, $101.9M financing cash, $61.3M investing outflow
Risk Factors
- No material changes or newly identified risks since the December 31, 2016 Form 10-K
- Carried-forward risks remain unchanged from the February 28, 2017 annual filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Penumbra Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 7, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 7, 2018
- Q1 2018 10-QFiled May 8, 2018
- Q2 2017 10-QFiled Aug 8, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 3, 2016
- Q2 2016 10-QFiled Aug 9, 2016
- Q1 2016 10-QFiled May 9, 2016
- Q3 2015 10-QFiled Nov 12, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.